On September 1st, JMDNA (Shanghai) Bio-Medical Tech Co., Ltd. (JMDNA) and Shenzhen MGI Tech Co., Ltd. (MGI) held a cooperation signing ceremony and officially unveiled the first High-throughput Sequencing Technology Innovation and Application Demonstration Center in China. The Center will provide integrated high-throughput sequencing service in the Yangtze River Delta, a region including Shanghai, southern Jiangsu province and northern Zhejiang province, using the world’s highest-daily-th...

On August 31, Shenzhen Haplox Biotechnology Co., Ltd. (Haplox) and Shenzhen MGI Technology Co., Ltd. (MGI) officially announced their cooperation. Xu Mingyan, founder and CEO of Haplox, Yu Dejian, President of MGI, and other representatives attended the signing ceremony. According to the agreement, Haplox will build on the technical advantages of MGI’s DNBSEQ high-throughput sequencing platform and combine its own technologies in the fields of liquid biopsy to jointly promote the develop...

In the last four decades, Professor Dr. Hans Lehrach has been one of the greatest pioneers and leading international personalities in functional and structural genome analysis research. In particular, his scientific activities and visions have contributed to accelerating the research approaches to these disciplines, especially in Germany. In 1978, as group leader at European Molecular Biology Laboratory in Heidelberg, Professor Dr. Lehrach contributed to develop positional cloning strate...

MGI has continued to advance lab automation with the launch of the first-of-its-kind high-throughput automated sample transfer processing system, MGISTP-7000. The product received the EU CE marking on August 14, 2020 and received Class I medical device qualification by the China’s NMPA on August 7, 2020, which streamlines the efficiency of front-end infectious sample handling across multiple regions. MGISTP-7000 integrates tube uncapping, tube recapping, barcode identification, automated...

Regarding the patent lawsuit initiated by Illumina against MGI in Hong Kong, the specific impact has yet to be determined. MGI believes that this patent litigation is an obvious attempt by Illumina to maintain a monopolistic market position and suppress the development of the industry. We intend to vigorously defend our intellectual property, and we have filed patent litigation against Illumina in U.S. District Court in California and Delaware. MGI has an extensive patent portfolio in the fiel...

China’s first “hospital version” of the Huo-Yan lab with MGI equipment has been established in the Third People’s Hospital of Shenzhen, a national clinical medical research center for infectious diseases. The hospital plans to build an automatic molecular detection platform for infectious diseases, promote rapid diagnosis and large-scale detection of pathogenic microorganisms, and enhance clinical inspection capability. This package also helps the hospital complete full technical prep...